Sequenom Posts 27 Percent Q3 Revenue Growth as It Plans FDA Talks on T21 Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its third-quarter revenues increased 27 percent, as sales for both its consumables and MassArray instruments grew year over year.

The San Diego-based firm reported total revenues of $11.7 million for the three-month period ended Sept. 30, compared to revenues of $9.2 million for the third quarter of 2009. It beat analysts' consensus estimate of $11.3 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.